CancerDrs

Lymphoma clinical trials in Pennsylvania

61 actively recruiting lymphoma trials at 27 sites across Pennsylvania.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Pocono Medical Center — East Stroudsburg, Pennsylvania
  • Lehigh Valley Hospital-Hazleton — Hazleton, Pennsylvania
  • University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Pennsylvania:
  • Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Pennsylvania:
  • Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • Forbes Hospital — Monroeville, Pennsylvania
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
  • Allegheny General Hospital — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…

Sponsor: BeOne Medicines
NCT ID: NCT05100862
Sites in Pennsylvania:
  • Mainline Health Lankenau Institute For Medical Research — Wynnewood, Pennsylvania
  • Cancer Care Associates of York — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…

Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Pennsylvania:
  • Geisinger Medical Center — Danville, Pennsylvania
  • Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
  • Community Medical Center — Scranton, Pennsylvania
  • Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Pennsylvania:
  • Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002) — Broomall, Pennsylvania
  • Cancer Care Associates Of York ( Site 0005) — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Pennsylvania:
  • Hospital of the University of Pennsylvania (Adults only) — Philadelphia, Pennsylvania
  • The Children's Hospital of Philadelphia Oncology Division, Blood & Marrow Transplant Section (Pediatrics) — Philadelphia, Pennsylvania
  • University of Pittsburgh Medical Center (Adults only) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…

Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Pennsylvania:
  • Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
  • McGlinn Cancer Institute — West Reading, Pennsylvania
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05139017
Sites in Pennsylvania:
  • Alliance Cancer Specialists (ACS) ( Site 8001) — Horsham, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lympho…

Sponsor: Ono Pharmaceutical Co., Ltd.
NCT ID: NCT07104032
Sites in Pennsylvania:
  • UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Sites in Pennsylvania:
  • Cancer Care Associates of York — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…

Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Pennsylvania:
  • Lehigh Valley Topper Cancer Center Institute — Allentown, Pennsylvania
  • Thomas Jefferson University — Philadelphia, Pennsylvania
  • West Penn Hospital — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…

Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…

Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Pennsylvania:
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-…

Sponsor: Genmab
NCT ID: NCT05283720
Sites in Pennsylvania:
  • Thomas Jefferson University Hospital /ID# 242077 — Philadelphia, Pennsylvania
  • Fox Chase Cancer Center /ID# 242106 — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT ID: NCT04920617
Sites in Pennsylvania:
  • Allegheny Health Network (AHN) West Penn Hospital — Pittsburgh, Pennsylvania
  • Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …

Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Pennsylvania:
  • Penn State Milton S Hershey Medical Center — Hershey, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia (CHOP) ( Site 1021) — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymph…

Sponsor: Dren Bio
NCT ID: NCT05475925
Sites in Pennsylvania:
  • Dren Investigational Site 2 — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate t…

Sponsor: Cellectis S.A.
NCT ID: NCT04150497
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →

Showing 25 of 61 trials with sites in Pennsylvania. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07